Safety and efficacy of high-dose cyclophosphamide, etoposide and ranimustine regimen followed by autologous peripheral blood stem cell transplant for patients with diffuse large B-cell lymphoma

Autor:	Katsuhiro Miura, Yoshihito Uchino, Jin Takeuchi, Yoshimasa Kura, Masami Takei, Noriyoshi Iriyama, Satomi Kiso, Yukio Hirabayashi, Yoshihiro Hatta, Akira Horikoshi, Masahiko Sugitani, Machiko Kusuda, Umihiko Sawada, Hitomi Kodaira, Hiromichi Takahashi, Daisuke Kurita, Sumiko Kobayashi, Mai Yagi, Yujin Kobayashi, Masaru Nakagawa, Atsuko Hojo
Rok vydání:	2014
Předmět:	Adult Male Oncology Cancer Research medicine.medical_specialty Transplantation Conditioning Cyclophosphamide medicine.medical_treatment Follicular lymphoma Kaplan-Meier Estimate Ranimustine Transplantation Autologous Disease-Free Survival Nitrosourea Compounds Young Adult Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Etoposide Retrospective Studies Peripheral Blood Stem Cell Transplantation Chemotherapy Dose-Response Relationship Drug business.industry Hematology Middle Aged medicine.disease Combined Modality Therapy Lymphoma Surgery Regimen Treatment Outcome Disease Progression Female Lymphoma Large B-Cell Diffuse Neoplasm Recurrence Local business Diffuse large B-cell lymphoma medicine.drug
Zdroj:	Leukemia & Lymphoma. 55:2514-2519
ISSN:	1029-2403 1042-8194
DOI:	10.3109/10428194.2014.889827
Popis:	We retrospectively evaluated the safety and efficacy of high-dose chemotherapy consisting of cyclophosphamide, etoposide and ranimustine (CEM) with autologous peripheral blood stem cell transplant (PBSCT) in 55 adult patients with relapsed or high-risk de novo diffuse large B-cell lymphoma (DLBCL) or DLBCL associated with follicular lymphoma. This included 36 patients in the upfront setting in their first complete remission. The median follow-up of 42 patients surviving at the time of the analysis was 52 months (range 1-159). Relapse or disease progression after PBSCT was a frequent cause of death, but no therapy-related mortality associated with PBSCT was observed. The 5-year overall survival and progression-free survival were 70.6% (95% confidence interval [CI], 54.0-82.1) and 57.0% (95% CI, 39.5-71.2), respectively. Chronic renal impairment, therapy-related myelodysplastic syndrome and prostate cancer were the major late complications. The CEM regimen is a tolerable, effective conditioning regimen for autologous PBSCT for DLBCL, with no therapy-related mortality observed.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0efa81922e7c8e947895af848c1e3cab https://doi.org/10.3109/10428194.2014.889827 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.